1 April 2016 - Crizotinib (Xalkori) has been available since 2012 for patients with advanced non-small cell lung cancer (bronchial carcinoma) who have a high activity of the enzyme anaplastic lymphoma kinase (ALK) and have already received another treatment. In November 2015, approval was extended to include first-line treatment.

After its assessment in 2013, the German IQWiG has reassessed the added benefit of the drug in comparison with the appropriate comparator therapy and found that an additional benefit of crizotinib for the first-line treatment of advanced bronchial carcinoma is not proven.

For more details, go to: https://www.iqwig.de/en/press/press-releases/press-releases/bronchial-carcinoma-added-benefit-of-crizotinib-for-first-line-treatment-not-proven.7232.html

To see the entries for crizotinib in the MAESTrO database, click here: https://app.maestrodatabase.com/app/reimbursement/browse/technology/crizotinib